Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (CONVERT)
A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment
Sponsor: Insmed Incorporated
Listed as NCT02344004, this PHASE3 trial focuses on Mycobacterium Infections, Nontuberculous and remains completed. Sponsored by Insmed Incorporated, it has been updated 11 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2020 — Jun 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Insmed Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.